Clinical Application of Zanubrutinib in B-Cell Lymphoma --Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 965-969, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-939717
ABSTRACT
Zanubrutinib is a highly selective second-generation BTK inhibitor developed in China and first approved by the U.S. Food and Drug Administration (FDA) as a novel antineoplastic drug. In recent years, with the birth of molecularly targeted drugs, the treatment of B-cell lymphoma have entered the era of targeted therapy, and immunotherapy has been widely accepted. Especially in some relapsed and refractory lymphomas, zanubrutinib has shown deep and sustained remissions and a favorable safety, which lays a foundation for precision therapy. In this review the clinical application and new progress for zanubrutinib in B-cell lymphoma was summarized briefly.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Piperidinas
/
Pirazoles
/
Pirimidinas
/
Linfoma de Células B
/
Inhibidores de Proteínas Quinasas
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS